archive-edu.com » EDU » W » WAYNE.EDU

Total: 427

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Core Services at Wayne State University - Division of Research
    php Aliccia Bollig Fischer Ph D contact person Behavioral and Field Research Core http www karmanos org bfrc Lisa C Berry Bobovski M A scientific director Biostatistics Core http www karmanos org biostats Judith Abrams Ph D director Clinical Trials Office www karmanos org cto Helen Peck RN MA OCN CCRP director Lawrence E Flaherty M D medical director Epidemiology Research Core http www karmanos org ERC Jennifer L Beebe Dimmer MPH Ph D director Fawn D Vigneau JD MPH co director High Throughput Assay Development and Pilot Screening Core https waynestate corefacilities org service center show external 3677 high throughput screening facility Andrew Fribley Ph D director Lipidomics Core http lipidomics wayne edu Krishna Rao Maddipati Ph D Director Lumigen Instrument Center Judy Westrick Ph D director NMR http chem wayne edu lumigen nmr lab html Bashar Ksebati Ph D manager Mass Spectrometry http chem wayne edu lumigen MassSpectrometry Lab html Yuriy Danylyuk Ph D manager X Ray Crystallography http chem wayne edu lumigen X Ray lab html Philip Martin Ph D manager Electron Microscopy Instrumentation http chem wayne edu lumigen microscopy instruments html Mike Mei Ph D manager Small Analytical Instruments http chem wayne edu lumigen SmallInstruments html Nicole Lenca Graduate Student Microscopy Imaging and Cytometry Resources Core http www med wayne edu micr Kamiar Moin Ph D director Jessica Back Ph D associate director MR Research Facility http www mrc wayne edu E Mark Haacke Ph D director nmrimaging aol com MR Research Facility Clinical Imaging http www mrc wayne edu index php site equipment see top of page Norman Cheng Ph D director 3T yxc16 wayne edu MR Research Facility Preclinical Imaging http www mrc wayne edu index php site equipment see bottom of page Bruce Berkowitz Ph D director 7T baberko med wayne edu 11

    Original URL path: http://research.wayne.edu/core_services.php (2016-02-13)
    Open archived version from archive


  • Welcome - eProtocol - Division of Research
    user acceptance testing of the Conflict of Interest e COI module Phase one of eProtocol also will include the launch of the Institutional Animal Care and Use Committee IACUC module which will follow shortly after the launch of e COI Additional phases will include the launch of the Institutional Review Board IRB Division of Laboratory Animal Resources DLAR Radiation Safety RSC Biosafety IBC and Controlled Substances CS modules eProtocol will provide researchers with a faster more efficient mechanism for submitting tracking and overseeing their research programs and improve many of the services provided to Wayne State University researchers Some of the benefits of eProtocol will include Dashboard access and management of all study materials Streamlined data entry process Electronic approval signatures from any location Status tracking of required training for study team members Automated notifications of approaching deadlines Real time feedback on the status of reviews Incorporate amendments directly into new protocols Direct management of study personnel on protocols Provide study team members with 24 7 web access from any location Focus group sessions for each module were conducted with faculty committee members and staff to evaluate the software and make recommendations to improve the user experience The resulting user

    Original URL path: http://research.wayne.edu/ep/index.php (2016-02-13)
    Open archived version from archive

  • News and Announcements - Division of Research
    enzymes Results from this basic science research project provide an understanding of a major source of mutations that may drive tumor growth and also explains a key finding in microbial evolution DNA consists of two thin strands that are made up of the four bases which are arranged in specific sequences creating words and chapters that contain the secrets of the cell The two DNA strands are intertwined with each other to protect the bases from damage by chemicals and enzymes Unfortunately the cell must copy its DNA before it can divide This copying process requires that the two DNA strands are briefly separated making DNA single stranded and thus susceptible to damage According to Bhagwat an odd quirk of DNA biochemistry is that one of the DNA strands known as the lagging strand template LGST stays single much longer than its counterpart the leading strand template LDST The WSU IU team showed that APOBEC3 enzymes preferentially attack the LGST causing mutations during DNA copying We did this work using the simple bacterium Escherichia coli as a model introducing the active part of the human enzyme APOBEC3G in it said Bhagwat The advantage of using E coli is that its complete DNA sequence can be easily determined and the way it copies its DNA is well understood Bhagwat s research team has been studying the larger AID APOBEC family of enzymes for the past 14 years and has helped show that this family of enzymes converts C to an abnormal base called Uracil U The U gets repaired back to C most of the time but sometimes this process fails and U is fixed as a T This is called a C to T mutation Bhagwat initiated collaboration with Patricia Foster Ph D at Indiana University and provided her group the A3G gene to express in E coli They determined the DNA sequence of hundreds of such bacteria and cataloged more than 1 000 mutations caused by A3G Weilong Hao Ph D assistant professor of biological sciences at Wayne State later analyzed the mutations and noticed that when A3G was in the cells C s in the LGST were replaced with T s three to four times the frequency at which they were getting replaced in the LDST Statistical analysis of the data showed that this occurrence was extremely unlikely to happen by chance which means that APOBEC3 enzymes must target the LGST Cancer is often called a genetic disease because nearly all cancer causing agents cause mutations When the DNA sequence of breast tumors and other cancers was recently determined C to T were the most frequently found mutations These mutations were often found in clusters suggesting that large stretches of DNA must become damaged in a single mutational event These mutations had the signature of mutations caused by APOBEC3 enzymes but it was unclear where these enzymes found the necessary long stretches of single stranded DNA to mutate said Bhagwat The work by our collaborative team has shown

    Original URL path: http://research.wayne.edu/news.php?id=18652 (2016-02-13)
    Open archived version from archive

  • News and Announcements - Division of Research
    University technology enters exclusive license agreement with TRImaran Pharma Inc to develop new class of drugs February 8 2016 Offers hope to patients with PTSD MDD depression ADHD and other neurological disorders DETROIT Wayne State University recently entered into an exclusive license agreement with TRImaran Pharma Inc for a class of novel drugs developed at Wayne State University that aims to offer hope in the treatment of post traumatic stress disorders PTSD depression ADHD and other neurological disorders Aloke Dutta Ph D professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State has developed promising lead molecules based on unique pyran molecular structures known as triple reuptake inhibitors TRI to address the current therapeutic need for treating depression PTSD and other neurological disorders including Parkinson s disease These drugs enhance three key monoamine neurotransmitters serotonin norepinephrine and dopamine by blocking monoaminergic transporters in the brain prolonging neurotransmitter activity between brain cells and thereby producing therapeutic effects According to Dutta these pyran based drugs can almost be tuned to provide the appropriate ratio for each disease and disorder All three neurotransmitters are known to play important roles in numerous neuronal processes including mood anxiety stress responses depression cognition attention urinary flow pain impulse control and more said Dutta Based on these roles enhancing their transmission is thought to be a sound approach to treating abnormalities in these processes We are pleased to be able to partner with Wayne State University and Professor Dutta to advance the development of such high potential drug candidates said Frank Bymaster chief scientific officer of TRImaran The currently used medications for our target indications PTSD MDD and ADHD have low efficacy and troublesome adverse events We believe Dr Dutta s triple reuptake inhibitors will be able to meet the

    Original URL path: http://research.wayne.edu/news.php?id=18632 (2016-02-13)
    Open archived version from archive

  • News and Announcements - Division of Research
    Teaching Learning Resources Centers Institutes Directory Policy on Centers Institutes Starting a Center Institute Center Institute Review Review Committees Undergraduate Research The Graduate School The Front Door for Business Engagement IBio Research Home News and Announcements Return to News List Wayne State chemistry professor earns prestigious NSF CAREER Award to examine unusual chemical structures February 3 2016 Will provide outreach programs to women and minorities DETROIT Wayne State University s Jennifer Stockdill Ph D assistant professor of chemistry in the College of Liberal Arts and Sciences has been awarded a 650 000 National Science Foundation NSF Faculty Early Career Development CAREER Award The CAREER Award is the most prestigious award given by the NSF and is designed to support junior faculty members who have shown exceptional promise through outstanding research excellent teaching and the integration of education and research by awarding assistant professors with five years of funding Stockdill s proposal Harnessing the Reactivity of Neutral Aminyl Radicals for Complex Heterocycle Synthesis will advance understanding of reactions that form novel chemical structures This research has numerous implications for understanding basic reactivity increasing the diversity of complex molecules available to high throughput screening libraries and ultimately aiding in the advancement of drug discovery The NSF funding will also support the implementation of an outreach program aimed at advancing women and minorities in science Through Stockdill s program these outreach activities will teach basic organic chemistry concepts to middle school girls instilling an enthusiasm for scientific discovery improving interactive learning tools for undergraduate education and creating a support network for graduate students in STEM fields Receiving this CAREER Award signals that the organic chemistry community has recognized our lab s achievements and supports the continuation of our work said Stockdill It s certainly an exciting time in the lab as we look

    Original URL path: http://research.wayne.edu/news.php?id=18592 (2016-02-13)
    Open archived version from archive

  • News and Announcements - Division of Research
    past decade complicating treatment options for these infections and creating a critical need to maximize the effectiveness of currently available drug treatments Michael Rybak Pharm D M P H professor of pharmacy practice in Wayne State University s Eugene Applebaum College of Pharmacy and Health Sciences and adjunct professor of medicine in WSU s School of Medicine recently received a five year 1 9 million grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health His research project aims to further explore treatment of these problematic bacteria in the hospital setting This project A Pharmacologic Approach to Prevent Daptomycin Resistance in VRE will explore various dosing regimens of daptomycin DAP a lipopeptide antibiotic for VREfm According to Rybak enterococcal organisms such as Enterococcus faecium Efm are highly problematic pathogens in the hospital setting and are responsible for life threatening infections including intra abdominal infections urinary tract infections endocarditis bloodstream infections and infections transmitted by medical devices Vancomycin is a powerful antibiotic that treats enterococcal infections but many Efm infections are now resistant even to vancomycin leaving few options that will treat this illness and save the lives of many of these patients Daptomycin DAP has demonstrated bactericidal activity against VREfm in vitro but the development of resistance during therapy has threatened its viability for future use said Rybak Our research will evaluate several dosing regimens of DAP against VREfm strains in the DAP susceptible minimum inhibitory concentration range with genetically proven proclivity for DAP resistance development We will also evaluate several beta lactam antibiotics in combination with DAP at optimized dosing regimens to determine the optimal beta lactam antibiotic to use with DAP against VREfm lowering the necessary dose exposures of DAP for clinical success and successfully prevent the emergence of DAP resistance Rybak

    Original URL path: http://research.wayne.edu/news.php?id=18438 (2016-02-13)
    Open archived version from archive

  • News and Announcements - Division of Research

    (No additional info available in detailed archive for this subpage)
    Original URL path: /news.php (2016-02-13)


  • Conflict of Interest - Conflict of Interest - Division of Research
    Consistent with NIH s March 2012 policy clarification concerning disclosure requirements for reimbursed and sponsored travel See Frequently Asked Questions E 1 posted on NIH s Office of Extramural Research Financial Conflict of Interest FCOI Web site Investigators who are planning to participate in PHS funded research must disclose their Significant Financial Interests SFIs over the previous twelve month period to their Institution no later than at the time of application for PHS funded research As with other SFIs defined in 42 CFR 50 603 the Investigator must disclose his her interests as well as those of the Investigator s spouse and dependent children that reasonably appear to be related to the Investigator s institutional responsibilities During the rule making process we considered how to best balance the need for the Institution to have information on an Investigator s reimbursed or sponsored travel versus the added burden on the Investigator to disclose the value of travel reimbursements Particularly in the case of sponsored travel which is paid on behalf of the Investigator the exact monetary value may not be readily available to the Investigator The Final Rule therefore does not require Investigators to disclose the monetary value of the sponsored or reimbursed travel rather it is the Institution s responsibility to determine upon review if further information such as the monetary value of the travel is needed Accordingly the Final Rule does not impose a general requirement to apply the de minimis threshold to all reimbursed or sponsored travel disclosure With that said in response to requests for further clarification we want to make clear that Institutions may within the discretion afforded by the Final Rule impose the 5 000 de minimis threshold to reimbursed or sponsored travel disclosure in their institutional policies which specify the disclosure details For example consistent with the requirement for other types of financial interests within the regulatory definition of SFI Institutions could apply the de minimis threshold when aggregated per entity Disclosure of reimbursed or sponsored travel is also subject to the exclusions described in 50 603 3 However it remains NIH s position that Investigators must disclose their SFIs including reimbursed or sponsored travel no later than at the time of application over the previous twelve month period initial disclosure which is also the same disclosure requirement that applies to all other SFIs The initial disclosure of SFIs over the previous twelve month period provides baseline information that allows Institutions to take into account whether Investigators have an ongoing financial relationship with an entity providing a payment or reimbursement or whether the payment or reimbursement was limited in duration Once Investigators have made their initial disclosure they are required to update their disclosures within 30 days of discovering or acquiring a new SFI and annually during the period of award We believe that these disclosure requirements provide Institutions with a comprehensive understanding of an Investigator s SFIs related to the PHS funded research project In addition to this Notice NIH will post and

    Original URL path: http://research.wayne.edu/coi/index.php (2016-02-13)
    Open archived version from archive